Zai LabZLAB
Recorded

Zai Lab Study update

Review the key takeaways and the transcript of this earnings call.

Period 0Duration33 minParticipants7

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello, ladies and gentlemen. Thank you for standing by, and welcome to Zai Lab's 2026 ACAAI Investor Call. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. As a reminder, today's call is being recorded. It is now my pleasure to turn the floor over to Rafael Amado, President and Head of Research and Development of Zai Lab. Please go ahead, sir. Good morning, everyone.

Rafael AmadoPresident and Head of Research and Development

Thank you for joining us today. My name is Rafael Amado, and I am President and Head of Research and Development for Zai Lab. Later this afternoon, at the American College of Allergy, Asthma & Immunology Annual Meeting, we will be presenting the first clinical data for ZL-1503, our internally discovered long-acting bispecific antibody that blocks both IL-13 cytokine ligand and IL-31 receptor alpha. We went into the phase I/I-B study with clear questions about safety, half-life, and target engagement. ZL-1503 met every objective that we tested in this healthy volunteer study. The study continues with further follow-up and multiple ascending doses in patients with atopic dermatitis. This MAD data will be available in the first half of next year. Our forward-looking statements are on slide two.

Rafael AmadoPresident and Head of Research and Development

Moving to today's agenda, I will walk through the highlights of our presentation at the conference and what it means for the program, and then I will open up for questions and answers. Briefly, for context on our global R&D programs, ZL-1503 is our leading immunology program. zoci, our DLL3 antibody-drug conjugate, is our lead oncology program, with registrational data in extrapulmonary neuroendocrine carcinomas and small cell lung cancer next year, setting us up for our first potential U.S. submission next year. Other global oncology programs are listed, including an additional ADC currently in phase I, a T-cell engager, and immunocytokine, both in IND-enabling studies for INDs in December of this year and the first quarter of next year, respectively. Today, though, the focus is entirely on ZL-1503. Therapies for atopic dermatitis are evaluated across key attributes: lesion control, itch relief, dosing convenience, and safety.

Rafael AmadoPresident and Head of Research and Development

We designed the phase I/I-B program to test ZL-1503 across each one of these attributes. Here is what the healthy volunteer data set showed us. On IL-13 blockade, a single dose of ZL-1503 produced at least 90% inhibition of pSTAT, or phospho-STAT, through at least week 12 at 200, 600, and 1,000 milligrams in peripheral blood. We are seeing strong IL-13 pathway inhibition. Second, dosing. The mean terminal half-life was approximately 40 to 50 days, with dose-proportional exposure. This supports the potential for extended dosing in maintenance. Third, safety. There were no serious adverse events, no dose-limiting toxicities, and no anti-drug antibodies detected as of the data cutoff. The fourth question, itch, needs data from patients with atopic dermatitis, which we plan to present next year.

Rafael AmadoPresident and Head of Research and Development

That said, we have already some compelling preclinical data demonstrating IL-31 receptor alpha blockade comparable to nemolizumab in vitro and sustained itch suppression for up to 112 days in non-human primates and a transgenic murine model. I want to explain why itch matters so much in atopic dermatitis and why we designed ZL-1503 to target it directly. Itch is among the most distressing symptoms for this disease. More than half of adults with atopic dermatitis name it as the most burdensome symptom. Nearly three-quarters of patients with more extensive disease report severe itch in the previous week, and more than 90% report moderate to severe sleep disturbance. Overall, severe atopic dermatitis has an enormous impact in health-related quality of life, comparable or worse in some domains to chronic conditions such as heart disease or diabetes, according to peer-reviewed journals. Itch also contributes to the disease.

Rafael AmadoPresident and Head of Research and Development

Itching leads to scratching disrupts the skin barrier, allergens and irritants penetrate the skin, and inflammation can be perpetuated, preventing pruritus improvement. ZL-1503 targets two clinically validated pathways. IL-13 drives the inflammatory cascade through Th2 differentiation, eosinophil and mast cell activity, and IgE production. IL-31 signaling through IL-31 receptor alpha activates sensory nerves that drive itch. IL-4 receptor alpha blockade can increase IL-4 and can also alter Th2/Th1 balance, leading to a degree of autoimmune dysregulation. IL-4 tends to be lesional in the skin, while IL-13 is diffusely distributed. The biology is proven. The question is whether one molecule can hit both cleanly with less frequent dosing. We think ZL-1503 can. ZL-1503 is a full IgG antibody against IL-13 with a single domain VHH targeting IL-31 receptor alpha fused to the N-terminus of the light chain of anti-IL-13 antibody. The molecule is 171 kilodaltons.

Rafael AmadoPresident and Head of Research and Development

The Fc region carries leucine replacement with alanine double mutations to reduce effector function, and YTE mutations to extend serum half-life, supporting the potential for longer dosing intervals. Preclinically, ZL-1503 strongly inhibited both IL-13 and IL-31 signaling and had a favorable safety profile. Turning to itch, because IL-31-driven itch can't be measured in healthy volunteers, I wanted to share our data with our preclinical models. We tested both arms in non-human primates. A single intravenous dose produced dose-dependent suppression of monkey IL-31-induced scratching. The left panel shows PK showing dose-dependent exposure, and on the right panel, we see at 10 milligrams per kilogram, one dose suppressed scratching through day 112, counted utilizing artificial intelligence. Duration of inhibition tracked exposure, so we saw a clear PK/PD relationship. This preclinical data gives us confidence that ZL-1503 can deliver meaningful itch relief.

Rafael AmadoPresident and Head of Research and Development

We look forward to sharing the first data in patients with atopic dermatitis. Now for the clinical data. Turning to our clinical program, ZL-1503-001 is a global, randomized, double-blind, placebo-controlled phase I/I-B study. The study has two parts. Part A, the single ascending dose portion we're presenting today, enrolled 48 healthy volunteers across six cohorts, randomized 6:2 to ZL-1503 or placebo in each cohort at intravenous doses from 50 milligrams to 1,000 milligrams. The primary endpoint is safety, with PK and immunogenicity as secondary endpoints, and phospho-STAT, TARC, CCL26, and IgE as pharmacodynamic biomarkers. Part B is a multiple ascending dose study in patients with moderate to severe atopic dermatitis. Two cohorts are included of 12 and 24 patients in two intravenous ascending doses. Alongside safety, PK, and biomarkers, it measures efficacy, lesion control by EASI and IGA, itch, and sleep.

Rafael AmadoPresident and Head of Research and Development

On the next slide, baseline characteristics were generally balanced across cohorts. The majority of participants were Caucasian or Asian. All healthy volunteers, cohorts 600 mg and 1,000 mg, include twice as many patients, as they were done as separate cohorts in China in addition to New Zealand. Moving to safety, ZL-1503 was well tolerated across all doses up to 1,000 mg. There were no serious adverse events, no dose-limiting toxicities, and no adverse events leading to treatment interruption. There was a single grade 3 TEAE in a placebo participant. Otherwise, toxicity mostly related to injection site complaints. There were no grade 3 or higher treatment-emergent events on ZL-1503 dose participants. Most frequently, adverse events were mild and related to study procedures such as bruising from blood draws. Next slide. Exposure increased proportionally with dose from 50 to 1,000 mg, and the mean terminal half-life was approximately 40 to 50 days across all doses, about twice the published half-lives of approved IL-4, IL-13, and IL-31 receptor antibodies.

Rafael AmadoPresident and Head of Research and Development

PK was consistent with our Chinese and New Zealand cohorts at 600 and 1,000 mg. Importantly, no anti-drug antibodies were detected as of the data cutoff across all those ZL-1503 participants. In summary, first, the YTE half-life extension prolongs exposure in humans. Second, dose-proportional PK profile gives us a reliable basis for modeling regimens from 50 to 1,000 mg. And third, the absence of detectable anti-drug antibodies is encouraging as we move towards repeat dosing. Ultimately, our goal is to identify a regimen that can provide both lesion control and rapid and sustained itch relief with less frequent dosing. Next slide. We assessed IL-13 pathway inhibition with four biomarkers.

Rafael AmadoPresident and Head of Research and Development

Phospho-STAT is the most direct. Inhibition of IL-13-stimulated STAT phosphorylation shows the pathway is blocked. TARC and CCL26 are downstream chemokines that reflect type 2 helper cell-mediated inflammation, and IgE is a broader marker of type 2 immune activity. These biomarkers help show whether ZL-1503 engages its target and suppresses the downstream signaling that drives disease. On phospho-STAT, a single dose of ZL-1503 produced rapid, near-complete inhibition of IL-13-stimulated phospho-STAT. Inhibition was evident in the first post-dose measurement at 200, 600, and 1,000 mg, and it was 90% or greater through week 12. Phospho-STAT was not measured between weeks 12 and 24. The 1,000 mg week 24 result wasn't available at the data cutoff. The duration of inhibition was dose-dependent, consistent with the PK that we just saw. The results show durable blockade of the IL-13 pathway, supporting the potential for extended dosing intervals.

Rafael AmadoPresident and Head of Research and Development

ZL-1503 also reduced TARC, or thymus activation regulated chemokine, also known as CCL17. TARC is a downstream chemokine associated with atopic dermatitis severity, produced by skin cells, dendritic cells, and endothelial cells that attract T helper cells to inflamed skin during the acute phase of atopic dermatitis. Single doses reduce circulating TARC across dose levels comparable to what's been reported with dupilumab. TARC levels are low in these healthy volunteers, but in spite of that, we see meaningful TARC suppression. Beyond TARC, ZL-1503 reduced CCL26, an IL-13-inducible chemokine linked to eosinophil recruitment. Reductions of 20% to 30% appear within the first week across all active doses, while placebo remained flat, and they persisted through week 24. We also saw an early trend towards IgE at higher doses.

Rafael AmadoPresident and Head of Research and Development

IgE declines slowly because of its long half-life, so longer follow-up and data in patients with atopic dermatitis will give us a clearer picture. In summary, pSTAT, TARC, and CCL26 show that ZL-1503 inhibits IL-13 signaling and its downstream effects, which transcends beyond the time of IC90 for pSTAT suppression in the case of CCL26 and IgE. What does this mean for patients? Today's patients face trade-offs. IL-13 and IL-4 receptor antibodies provide strong lesion control, but itch relief takes longer. Nemolizumab provides rapid itch relief with more modest lesion control. JAK inhibitors offer both, but carry a boxed warning. ZL-1503 is designed to remove those trade-offs. Lesion control is in line with the IL-13 class, rapid itch relief through IL-31 receptor alpha blockade. We believe that comprehensively interrupting the itch-scratch inflammation cycle has the potential to translate into best-in-class results for patients.

Rafael AmadoPresident and Head of Research and Development

Furthermore, on dosing, patients on dupilumab inject 26 times a year. With lebrikizumab and nemolizumab, maintenance is between 7 and 13. ZL-1503 has a half-life that is two times at least the approved agents and pSTAT inhibition that holds for months. ZL-1503 has the potential for maintenance dosing every three months or more, equating to about four injections a year after induction treatment. That's a reduction of up to 80% versus every two-week dosing with meaningful control of inflammation, in line with dupilumab and lebrikizumab, and rapid and persistent control of pruritus commensurate with nemolizumab. We see Q3 months as the optimal dosing schedule. Beyond that, the added convenience matters less. However, the final interval will be set by repeat dose data in patients and tested in phase II-B with a subcutaneous formulation. Lastly, ZL-1503 has demonstrated good safety.

Rafael AmadoPresident and Head of Research and Development

Taken together, we believe 1503 has a profile that can be highly differentiated in this market. Now, looking ahead, 2027 is an important year of catalysts. In the first half of 2027, we expect the first data in patients with atopic dermatitis from the multiple ascending placebo-controlled dose part of the phase I/I-B study, including PK, PD, lesion control, and itch. Our IV to subcutaneous bridging study is now fully enrolled, and we expect data in the first half of the year. Together, this data will guide dose and regimen selection for a global phase II-B study that we plan to initiate in 2027 using an already available subcutaneous formulation. We look forward to sharing updated data on this program throughout the year. With that, I'll open it up for questions.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day